--- title: "ACCG-2671 | PepTracker Pro" url: https://peptrackerpro.com/peptides/accg-2671 description: "An oral, once-daily small-molecule amylin receptor agonist in first-in-human Phase 1 testing for obesity — an early entrant in the race to make amylin biology available as a pill rather than an injection." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This page is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # ACCG-2671 Low Evidence An oral, once-daily small-molecule amylin receptor agonist in first-in-human Phase 1 testing for obesity — an early entrant in the race to make amylin biology available as a pill rather than an injection. Aliases ACCG2671 +3 more Evidence Low Evidence Last Updated 2026-06-14 Reading Time 3 min ## What It Is ACCG-2671 is an investigational oral, once-daily small molecule that activates the amylin receptor, being developed by Structure Therapeutics for the treatment of obesity. Amylin is a hormone co-secreted with insulin that promotes satiety and slows gastric emptying; amylin-based drugs (such as the injectable cagrilintide, eloralintide, and petrelintide) have emerged as one of the most promising non-incretin approaches to weight loss, valued for strong appetite control and the potential to preserve lean mass better than some GLP-1 regimens. Most amylin agonists are injectable peptides. ACCG-2671 is notable because it is a small molecule designed to be taken as a daily pill, created with Structure Therapeutics' structure-based drug-discovery platform to reproduce amylin biology orally. The company selected ACCG-2671 as its lead oral amylin candidate in December 2024 and announced the start of a first-in-human Phase 1 study in December 2025. That study evaluates safety, tolerability, pharmacokinetics, and pharmacodynamic activity in both healthy volunteers and people with obesity, using single-ascending-dose and multiple-ascending-dose cohorts. In preclinical work the company reported potent target engagement, robust weight loss as a standalone treatment and additional weight loss when combined with a GLP-1 receptor agonist, a favorable safety profile, and pharmacokinetics suitable for once-daily dosing. ACCG-2671 has no published human efficacy data yet, is not approved by any regulator, is not a marketed or compounded product, and is not on the FDA's July 2026 PCAC compounding review list. As a brand-new clinical-stage drug candidate, it should be distinguished sharply from the 'research chemical' compounds sold online. Also known as: ACCG2671, ACCG 2671, oral amylin small molecule, Structure Therapeutics amylin agonist ## Why Researchers Study It ACCG-2671 targets one of obesity medicine's most sought-after goals: delivering amylin biology — strong satiety and potential lean-mass advantages — in a convenient once-daily oral small molecule rather than an injectable peptide. Researchers are interested in whether an oral amylin agonist can match the weight loss of injectable amylin peptides, work as a standalone therapy or as an oral combination partner with GLP-1 drugs, and achieve acceptable gastrointestinal tolerability. It represents the next frontier after oral GLP-1 (orforglipron, oral semaglutide): an oral, mechanistically distinct partner that could broaden combination obesity therapy. ## Proposed Mechanisms - Activates the amylin receptor (calcitonin receptor paired with RAMP co-receptors) as a small-molecule agonist - Promotes satiety and reduces food intake through central amylin signaling - Slows gastric emptying to prolong post-meal fullness - Designed for oral, once-daily dosing rather than injection - Intended to act as a standalone agent or as an oral combination partner with GLP-1 receptor agonists ## Evidence Snapshot Low Evidence Low Medium High | Study Type | Model | Outcome | Link | | --- | --- | --- | --- | | Human (Phase 1, ongoing) | First-in-human single- and multiple-ascending-dose study in healthy volunteers and adults with obesity (initiated Dec 2025) | Evaluating safety, tolerability, pharmacokinetics, and pharmacodynamic activity; no results published yet | Source: https://www.globenewswire.com/news-release/2025/12/17/3206968/0/en/Structure-Therapeutics-Announces-Initiation-of-Phase-1-Clinical-Study-of-Oral-Small-Molecule-Amylin-Receptor-Agonist-ACCG-2671-for-the-Treatment-of-Obesity.html | | Preclinical (developer-reported) | Animal models of obesity, monotherapy and combination with a GLP-1 receptor agonist | Reported potent target engagement, robust weight loss alone and added weight loss in combination with a GLP-1 RA, favorable safety, and once-daily oral pharmacokinetics | Source: https://www.globenewswire.com/news-release/2024/12/17/2998609/0/en/Structure-Therapeutics-Announces-Selection-of-Lead-Oral-Small-Molecule-Amylin-Receptor-Agonist-ACCG-2671-for-the-Treatment-of-Obesity.html | ## Commonly Discussed Benefits Fat Loss: https://peptrackerpro.com/benefits/fat-loss Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism Researching ACCG-2671? Track it, set reminders, and keep notes in the free app. Track in App (https://app.peptrackerpro.com/?add=accg-2671) ## Safety & Cautions - No human efficacy or safety data have been published — a first-in-human Phase 1 study only began in December 2025 - Not approved by the FDA or any regulator; not a marketed, prescribed, or compounded product - Not on the FDA's July 2026 PCAC compounding review list and not legitimately available to consumers - All weight-loss and safety claims so far come from preclinical (animal) data reported by the developer - It is a small molecule, not a peptide, despite targeting the same amylin receptor as injectable amylin peptides - Most experimental amylin agonists cause gastrointestinal side effects (nausea, vomiting); the oral tolerability of ACCG-2671 in humans is not yet known ## Comparisons See how ACCG-2671 compares to related peptides: ACCG-2671 vs Amycretin: https://peptrackerpro.com/compare/accg-2671-vs-amycretin ACCG-2671 vs Cagrilintide: https://peptrackerpro.com/compare/accg-2671-vs-cagrilintide ACCG-2671 vs Eloralintide: https://peptrackerpro.com/compare/accg-2671-vs-eloralintide ACCG-2671 vs Petrelintide: https://peptrackerpro.com/compare/accg-2671-vs-petrelintide ACCG-2671 vs Semaglutide: https://peptrackerpro.com/compare/accg-2671-vs-semaglutide ACCG-2671 vs Tirzepatide: https://peptrackerpro.com/compare/accg-2671-vs-tirzepatide ## Calculator Tools Use our research tools to explore dosing and reconstitution data: Reconstitution Calculator: https://peptrackerpro.com/calculators ## Citations 1. [1] Structure Therapeutics — Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 (Dec 17, 2025) PubMed (https://www.globenewswire.com/news-release/2025/12/17/3206968/0/en/Structure-Therapeutics-Announces-Initiation-of-Phase-1-Clinical-Study-of-Oral-Small-Molecule-Amylin-Receptor-Agonist-ACCG-2671-for-the-Treatment-of-Obesity.html) 2. [2] Structure Therapeutics — Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 (Dec 17, 2024) PubMed (https://www.globenewswire.com/news-release/2024/12/17/2998609/0/en/Structure-Therapeutics-Announces-Selection-of-Lead-Oral-Small-Molecule-Amylin-Receptor-Agonist-ACCG-2671-for-the-Treatment-of-Obesity.html) 3. [3] Structure Therapeutics — ACCG-2671 Phase 1 initiation (investor relations) PubMed (https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-announces-initiation-phase-1-clinical) ### Keep researching in the app - Log ACCG-2671 to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack Open PepTracker Pro Free: https://app.peptrackerpro.com/?add=accg-2671 Browse more peptides: https://peptrackerpro.com/peptides ## Related Peptides ### Amycretin Medium Evidence A unimolecular GLP-1 and amylin receptor dual agonist in Phase 3 trials, available in both subcutaneous and oral formulations, with up to 22% weight loss in Phase 1b/2a. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+1 more View Details: https://peptrackerpro.com/peptides/amycretin \+ Compare: https://peptrackerpro.com/compare?select=amycretin Track in App: https://app.peptrackerpro.com/?add=amycretin ### Cagrilintide High Evidence A long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/cagrilintide \+ Compare: https://peptrackerpro.com/compare?select=cagrilintide Track in App: https://app.peptrackerpro.com/?add=cagrilintide ### Eloralintide Medium Evidence A selective, long-acting amylin receptor agonist in Phase 3 trials for obesity, offering a GLP-1-independent weight loss mechanism with up to 20.1% weight loss in Phase 2. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss View Details: https://peptrackerpro.com/peptides/eloralintide \+ Compare: https://peptrackerpro.com/compare?select=eloralintide Track in App: https://app.peptrackerpro.com/?add=eloralintide ### Petrelintide Medium Evidence A long-acting amylin analog in late-stage clinical development for chronic weight management, designed to deliver double-digit weight loss with a tolerability profile comparable to placebo. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation View Details: https://peptrackerpro.com/peptides/petrelintide \+ Compare: https://peptrackerpro.com/compare?select=petrelintide Track in App: https://app.peptrackerpro.com/?add=petrelintide ### Semaglutide High Evidence A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+3 more View Details: https://peptrackerpro.com/peptides/semaglutide \+ Compare: https://peptrackerpro.com/compare?select=semaglutide Track in App: https://app.peptrackerpro.com/?add=semaglutide ### Tirzepatide High Evidence A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis. View Details: https://peptrackerpro.com/peptides/tirzepatide \+ Compare: https://peptrackerpro.com/compare?select=tirzepatide Track in App: https://app.peptrackerpro.com/?add=tirzepatide ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "ACCG-2671", "description": "An oral, once-daily small-molecule amylin receptor agonist in first-in-human Phase 1 testing for obesity — an early entrant in the race to make amylin biology available as a pill rather than an injection.", "url": "https://peptrackerpro.com/peptides/accg-2671", "lastReviewed": "2026-06-14", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "ACCG-2671", "item": "https://peptrackerpro.com/peptides/accg-2671" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People following the race to develop an oral (pill) amylin drug for weight loss?", "acceptedAnswer": { "@type": "Answer", "text": "ACCG-2671 is a research peptide studied in preclinical models. An oral, once-daily small-molecule amylin receptor agonist in first-in-human Phase 1 testing for obesity — an early entrant in the race to make amylin biology available as a pill rather than an injection." } }, { "@type": "Question", "name": "Those comparing amylin agonists (cagrilintide, eloralintide, petrelintide) with GLP-1 drugs?", "acceptedAnswer": { "@type": "Answer", "text": "ACCG-2671 is a research peptide studied in preclinical models. An oral, once-daily small-molecule amylin receptor agonist in first-in-human Phase 1 testing for obesity — an early entrant in the race to make amylin biology available as a pill rather than an injection." } }, { "@type": "Question", "name": "Investors and researchers tracking Structure Therapeutics' obesity pipeline?", "acceptedAnswer": { "@type": "Answer", "text": "ACCG-2671 is a research peptide studied in preclinical models. An oral, once-daily small-molecule amylin receptor agonist in first-in-human Phase 1 testing for obesity — an early entrant in the race to make amylin biology available as a pill rather than an injection." } }, { "@type": "Question", "name": "People asking whether there is an oral alternative to injectable amylin or GLP-1 therapies?", "acceptedAnswer": { "@type": "Answer", "text": "ACCG-2671 is a research peptide studied in preclinical models. An oral, once-daily small-molecule amylin receptor agonist in first-in-human Phase 1 testing for obesity — an early entrant in the race to make amylin biology available as a pill rather than an injection." } } ] } ] ```